Zeaxanthin + Pembrolizumab for Advanced Cancer

"Data posted on clinicaltrials.gov reveals that recruitment is still open for this medical trial, which was first advertised to the public in April 2022 and most recently updated a year later."

"This research endeavour seeks 72 individuals with metastatic tumors, aged 18 to 99. Notably, all participants must meet the inclusion criteria for dose escalation of zeaxanthin monotherapy."

"Assessed on a scale of 1 to 3, the safety rating for Zeaxanthin Monotherapy is estimated at one due to it being an early-phase trial with limited evidence supporting its efficacy and safety."

"The requirements to be eligible for this trial demand that applicants are aged 18-99. In addition, 15 clinical trials exist specifically for minors and 229 studies encompass seniors of 65 years or older."

"Indeed, the data hosted on clinicaltrials.gov reveals that this medical examination is still in progress, having been initially posted on April 17th 2022 and recently updated on April 19th 2023. The trial requires 72 participants to be recruited at a single site."

"The primary objective of this clinical trial, which runs for approximately 20 weeks per dosing cohort, is to assess the efficacy of zeaxanthin monotherapy. Secondary endpoints include response rate (ORR) as measured by RECIST v1.1, progression free survival (PFS), and duration of response in patients with unresectable advanced solid tumors; all results will be evaluated at 2-month and 6-month intervals after treatment commencement. Additionally, disease control rate (percentage of participants achieving complete/partial remission or stable illness) will also be gauged."